Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019
April 10 2019 - 8:00AM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company developing novel precision antibacterials
to treat serious drug-resistant infections, today announced
multiple data presentations on ETX2514SUL and ETX0282CPDP as well
as its preclinical non-beta-lactam PBP inhibitor (NBP) program at
the 29th European Congress of Clinical Microbiology &
Infectious Diseases (ECCMID), taking place April 13-16, 2019 in
Amsterdam, Netherlands.
In addition to two oral presentations and five
poster presentations on the scientific program, Entasis Chief
Executive Officer Manos Perros, PhD will present in an
invitation-only industry panel discussion, “Therapeutics Pipeline
Corner,” to discuss Entasis’ unique research and development
strategies and updates on its portfolio of precision
antibiotics.
"Results from these studies further demonstrate
the potent antibacterial activity of our pipeline candidates
against specific pathogens and further support the recent
initiation of our ATTACK Phase 3 global pivotal trial of ETX2514SUL
in patients with Acinetobacter baumannii infections and the
continued development of ETX0282CPDP for the treatment of
antibiotic-resistant Enterobacteriaceae urinary tract infections,”
said Manos Perros, Chief Executive Officer, Entasis Therapeutics.
“We look forward to discussing these new datasets and innovative
strategies to combat the critical global issue of antibiotic
resistance with the infectious diseases community at ECCMID
2019.”
Oral Presentations:
Mini-Oral #300: A double-blind, randomized,
placebo-controlled study to evaluate the safety and efficacy of
intravenous sulbactam-ETX2514 in the treatment of hospitalized
adults with complicated urinary tract infections, including acute
pyelonephritis
- OE049 Mini-oral ePoster
Session: Clinical trials with recently approved or
late-stage development antibiotics
- Presenter: Subasree
Srinivasan, MD
- Timing: Saturday,
April 13th; 2:45-2:50 pm CEST
- Location: Arena
5
- ETX2514SUL in combination with
imipenem/cilastatin was generally safe and well-tolerated in
hospitalized patients with complicated urinary tract infections,
including acute pyelonephritis.
Panel Presentation: Therapeutics
Pipeline Corner
- Presenter: Manos Perros, PhD
- Timing: Sunday, April 14th at 12:15-1:15 p.m.
CEST
- Location: Arena 3
Oral Presentation #527: Discovery of a
novel series of penicillin-binding protein 3 inhibitors as
monotherapy for Pseudomonas aeruginosa infections: rational design
of biochemical potency and bacterial permeation
- Oral Presentation Session
OS100: Novel antimicrobial agents and discovery
strategies
- Presenter: Thomas
Durand-Reville, PhD
- Timing: Sunday, April
14th; 3:06-3:17 p.m. CEST
- Location: Hall M
- An innovative, two-prong, rational
design approach led to the discovery of a novel series of
diazabicyclooctanone analogs with the potential to treat
Pseudomonas aeruginosa infections.
ETX2514 Poster Presentations:
Poster #P1185: The novel beta-lactamase
inhibitor ETX2514 effectively restores sulbactam activity against
recent global Acinetobacter baumannii calcoaceticus complex
clinical isolates
- Poster Session PS069:
New beta-lactamase inhibitors: in vitro studies
- Presenter: Sarah M.
McLeod, PhD
- Timing: Sunday, April
14th; 1:30-2:30 p.m. CEST
- Location: Exhibit
Hall, Ground Level
- ETX2514SUL demonstrated potent
antibacterial activity against recent, geographically-diverse
clinical isolates of Acinetobacter baumannii calcoaceticus complex,
including multi-drug resistant isolates.
Poster #P1186: The susceptibility of global
isolates of Acinetobacter baumannii to ETX2514SUL and
comparators
- Poster Session PS069:
New beta-lactamase inhibitors: in vitro studies
- Presenter: Harald
Seifert, MD, University of Cologne, Germany
- Timing: Sunday, April
14th; 1:30-2:30 p.m. CEST
- Location: Exhibit
Hall, Ground Level
- ETX2514SUL had excellent in vitro
potency, including against isolates of carbapenem-resistant A.
baumannii that were pan-resistant to sulbactam, imipenem/meropenem,
colistin, and amikacin.
Poster #P1953: Population Pharmacokinetic
(PPK) and Pharmacokinetic-Pharmacodynamic (PKPD) Target
Attainment (TA) Analyses of ETX2514SUL to Support Dosing
Regimens in Patients with Varying Renal Function
- Poster Session PS113:
Recent research on the pharmacokinetics and safety of antibacterial
agents
- Presenter: Nikolas J.
Onufrak, PharmD, Institute for Clinical Pharmacodynamics, Inc.,
NY
- Timing: Monday, April
15th; 1:30-2:30 p.m. CEST
- Location: Exhibit
Hall, Ground Level
- The study showed that selected Phase 3
dosing regimens maximize PKPD target attainment for ETX2514SUL
across a broad range of renal function.
ETX0282 (ETX1317) Poster Presentations
Poster #P1184: The novel beta-lactamase
inhibitor ETX1317 effectively restores the activity of cefpodoxime
against recent global Enterobacteriaceae isolates from urinary
tract infections
- Poster Session PS069:
New beta-lactamase inhibitors: in vitro studies
- Presenter: Sarah M.
McLeod, PhD
- Timing: Sunday, April
14th; 1:30-2:30 p.m. CEST
- Location: Exhibit
Hall, Ground Level
- The combination of ETX1317 and
cefpodoxime demonstrated potent antibacterial activity against a
recent collection of geographically-diverse UTI isolates and was
unaffected by resistance phenotypes.
Poster #P1991: Efficacy of Cefpodoxime
proxetil and ETX0282 in a murine UTI model with E. coli and K.
pneumoniae
- Poster Session PS115:
Evaluation of diverse antimicrobials in vitro and experimental
models
- Presenter: William J.
Weiss, MS, University of North Texas (UNT) Health Science Center,
TX
- Timing: Monday, April
15th; 1:30-2:30 p.m. CEST
- Location: Exhibit
Hall, Ground Level
- The results demonstrate that ETX0282
rescues cefpodoxime efficacy in a urinary tract infection model
with both E. coli CTX-M-14 and K. pneumoniae KPC-2 clinical
isolates.
About EntasisEntasis is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel antibacterial products
to treat serious infections caused by multidrug-resistant
Gram-negative bacteria. Entasis’ targeted-design platform has
produced a pipeline of product candidates, including ETX2514SUL
(targeting A. baumannii infections), zoliflodacin (targeting
Neisseria gonorrhoeae), and ETX0282CPDP (targeting
Enterobacteriaceae infections). Entasis is also using its platform
to develop a novel class of antibiotics, non-β-lactam inhibitors of
the penicillin-binding proteins (NBPs) (targeting Gram-negative
infections). Both ETX0282CPDP and NBP are powered by CARB-X. For
more information, visit www.entasistx.com.
Entasis Company Contact Kyle Dow Entasis
Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations ContactLee RothThe Ruth
Group646-536-7012lroth@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Sep 2023 to Sep 2024